Pharmacopoeia plays a more and more important role in drug administration and other related areas. Good Pharmacopoeia Practices (GPhP) also increasingly shows its importance. Under the circumstance, GPhP issued by WHO represents special practical significance. This paper made a preliminary analysis and interpretation of the latest contents of WHO GPhP combined with the practical experience of the Chinese Pharmacopoeia.
Wang Xiaojuan, Cao Yan, Ma Rui, Xu Li, Guo Zhongping
. Discussion on WHO GPhP and the Significance to the Practice of Chinese Pharmacopoeia[J]. Chinese Pharmaceutical Affairs, 2017
, 31(10)
: 1158
-1164
.
DOI: 10.16153/j.1002-7777.2017.10.011
[1] Report on meetings of expert committees and study groups[EB/OL].[2016-10-10]. http://apps.who.int/gb/ebwha/pdf_files/EB139/B139_12-en.pdf.
[2] WHO. Technical Report Series,No. 996[EB/OL].[2016-10-10]. http://www.who.int/medicines/areas/quality_safety/quality_assurance/en/.
[3] Proceedings of the Tenth International Conference of Drug Regulatory Authorities (ICDRA)-Hong Kong, China,24-27 June 2002[Z]. 2002.
[4] International Nonproprietary Names for Pharmaceutical Substances (INN),WHO Drug Information Vol. 30, No. 1,2016[EB/OL].[2016-10-10]. http://www.who.int/medicines/publications/druginformation/innlists/RL75.pdf?ua=1.
[5] ICH guideline Q3A(R2)(Impurities in new drug substances)[EB/OL].[2016-10-10]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3A_R2/Step4/Q3A_R2__Guideline.pdf.
[6] ICH guideline Q3C(R5)(Impurities:guideline for residual solvents)[EB/OL].[2016-10-10]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3C/Step4/Q3C_R5_Step4.pdf.
[7] ICH guideline Q3B(R2)(Impurities in new drug products)[EB/OL].[2016-10-10]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3B_R2/Step4/Q3B_R2__Guideline.pdf.
[8] ICH guideline Q2(R1)(Validation of analytical procedures:text and methodology)[EB/OL].[2016-10-10]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf.
[9] WHO. Technical Report Series,No. 937,2006,Annex 4 Supplementary guidelines on good manufacturing practices:validation[EB/OL].[2016-10-10]. http://apps.who.int/iris/bitstream/10665/43443/1/WHO_TRS_937_eng.pdf.
[10] 中国药典:三部[S]. 2015.
[11] 中国药典:一部[S]. 2015.
[12] 国家药典委员会编. 国家药品标准手册[M]. 4版. 北京:中国医药科技出版社,2013.
